“We are getting too happy, for too little”: these words of a senior pharma journalist a decade back sound prophetic now. Consolidation, CRAMS, para IV filings and challenges to innovators, acquisitions, out-licensing, US and developed markets business growth – key themes a decade back – are now replaced with headwinds in US, pricing pressure in developed markets, quality issues, price regulation in domestic market, policy on generics only prescription, etc.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
